Lupin Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lupin Pharmaceuticals, Inc.
Industry Pharmaceuticals

Baltimore, Maryland

Baltimore, USA
Key people

Vinita Gupta, Group President & CEO, Lupin Pharmaceuticals, Inc.[1][2]

New leadership team at Lupin from September 2013[3]
Products Pharmaceuticals, branded and generic drugs, biotechnology, Advanced Drug Delivery Systems, New Chemical Entity Research, vaccines, Over-the-Counter drugs

Increase INR3769 crore (US$630 million) (2012-2013)

Parent Lupin Limited

Lupin Pharmaceuticals, Inc. (LPI), the U.S. subsidiary of Lupin Limited is headquartered in Baltimore, Maryland. The company has a presence in the branded as well as the generics markets in the US, and as of 2013, it remains one of the few Generics Pharma Majors with a substantial brands business in the US. With revenues of over $700 million in FY 2013, the company is the 5th largest and the fastest growing generics player in the US (5.3% market share by prescriptions, IMS Health). Lupin's US brands business contributed 21% of total US sales whereas the generics business contributed 79% during FY 2012-13.[6]